Prescient Therapeutics Reports Strong Progress in PTX-100 Phase 2a Study and New CMO Appointment
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics Ltd (ASX:PTX) has highlighted continued progress across its oncology development pipeline during the...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
As the Wise Man sayeth, one should giveth a task to a busy person if...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.